Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment. Andreessen Horowitz led the Series D ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals. Lynk’s program will be developed by Formation’s ...

NEW YORK, June 9, 2026 /PRNewswire/ -- Formation Bio, an AI-native pharma company, today announced dosing of the first participant in a Phase 1, first-in-human (FIH) clinical trial of BLKR201. The ...

Founders: Benjamine Liu (CEO), Linhao Zhang Launched: 2016 Headquarters: New York City Funding: $600 million Valuation: $1.7 billion (PitchBook) Key Technologies: Artificial intelligence, deep neural ...

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get ...

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals. This next-generation central ...

Formation Bio, a startup focused on applying AI to drug development with backing from OpenAI CEO Sam Altman, has raised over a quarter-billion dollars to support its ambitious product roadmap.

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune ...